{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:41:07Z","timestamp":1791247267486,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009634","name":"Susan G Komen Breast Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: CardioOncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jaccao.2026.07.009","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:57:59Z","timestamp":1789012679000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Cardiotoxicity of Biosimilar versus Reference Trastuzumab in Early HER2-Positive Breast Cancer"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0670-4960","authenticated-orcid":false,"given":"Inimfon","family":"Jackson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon H.","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Chavez-MacGregor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaccao.2026.07.009_bib1","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaccao.2026.07.009_bib2","doi-asserted-by":"crossref","DOI":"10.1093\/bjsopen\/zrac028","article-title":"Pathological complete response as a surrogate to improved survival in human epidermal growth factor receptor-2-positive breast cancer: systematic review and meta-analysis","volume":"6","author":"Davey","year":"2022","journal-title":"BJS Open"},{"key":"10.1016\/j.jaccao.2026.07.009_bib3","article-title":"Not all small HER2 positive breast cancers have the same clinical outcome in the North-East of Scotland","volume":"31","author":"Pawloy","year":"2022","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.jaccao.2026.07.009_bib4","doi-asserted-by":"crossref","first-page":".2081","DOI":"10.3390\/cancers12082081","article-title":"The changing paradigm for the treatment of HER2-Positive breast cancer","volume":"12","author":"Patel","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jaccao.2026.07.009_bib5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions","volume":"22","author":"Swain","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaccao.2026.07.009_bib6","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1471-2407-7-153","article-title":"Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials","volume":"7","author":"Viani","year":"2007","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jaccao.2026.07.009_bib7","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/S1470-2045(21)00288-6","article-title":"HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials","volume":"22","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaccao.2026.07.009_bib8","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-Positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaccao.2026.07.009_bib9","doi-asserted-by":"crossref","first-page":"7168","DOI":"10.1038\/s41598-023-34429-9","article-title":"Real world evidence of adjuvant trastuzumab in HER2 positive early breast cancer","volume":"13","author":"Lluch-G\u00f3mez","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaccao.2026.07.009_bib10","doi-asserted-by":"crossref","first-page":"e476","DOI":"10.1200\/OP.22.00639","article-title":"Biosimilar competition and payments in medicare: the case of trastuzumab","volume":"19","author":"Horn","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.jaccao.2026.07.009_bib11","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1080\/14712598.2019.1638362","article-title":"Biosimilars for breast cancer","volume":"19","author":"Migliavacca Zucchetti","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jaccao.2026.07.009_bib12","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3747\/co.25.3942","article-title":"The evolution of biosimilars in oncology, with a focus on trastuzumab","volume":"25","author":"Nixon","year":"2018","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jaccao.2026.07.009_bib13","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1200\/OP.22.00783","article-title":"ASCO policy statement on biosimilar and interchangeable products in oncology","volume":"19","author":"Rodriguez","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.jaccao.2026.07.009_bib14","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jamainternmed.2020.3997","article-title":"Assessment of availability, clinical testing, and US food and drug administration review of biosimilar biologic products","volume":"181","author":"Moore","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jaccao.2026.07.009_bib15","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1200\/JCO.20.02510","article-title":"Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer: ASCO guideline update","volume":"39","author":"Denduluri","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaccao.2026.07.009_bib17","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1161\/CIR.0000000000000426","article-title":"Drugs that may cause or exacerbate heart failure","volume":"134","author":"Page","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2026.07.009_bib18","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1248\/bpb.b25-00235","article-title":"Trastuzumab cardiotoxicity: mechanism and management","volume":"48","author":"Wakasa","year":"2025","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.jaccao.2026.07.009_bib19","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1161\/CIR.0000000000000556","article-title":"Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association","volume":"137","author":"Mehta","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2026.07.009_bib20","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10549-007-9663-z","article-title":"Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials","volume":"109","author":"Bria","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jaccao.2026.07.009_bib21","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cardfail.2011.10.015","article-title":"Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer","volume":"18","author":"Tarantini","year":"2012","journal-title":"J Card Fail"},{"key":"10.1016\/j.jaccao.2026.07.009_bib22","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/j.jacc.2012.07.068","article-title":"Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer","volume":"60","author":"Chen","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2026.07.009_bib23","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1200\/JCO.2013.48.7884","article-title":"Trastuzumab-related cardiotoxicity among older patients with breast cancer","volume":"31","author":"Chavez-MacGregor","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaccao.2026.07.009_bib24","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1177\/1060028020944596","article-title":"A clinical review of biosimilars approved in oncology","volume":"55","author":"Ngo","year":"2021","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jaccao.2026.07.009_bib25","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.5822","article-title":"Cardiac safety and efficacy of SB3 trastuzumab biosimilar for ERBB2-Positive early breast cancer: secondary analysis of a randomized clinical trial","volume":"6","author":"Pivot","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jaccao.2026.07.009_bib26","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00280-020-04156-3","article-title":"Comparative efficacy and safety of trastuzumab biosimilars to the reference drug: a systematic review and meta-analysis of randomized clinical trials","volume":"86","author":"Cargnin","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jaccao.2026.07.009_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1673372","article-title":"Comparative study of the impact of adjuvant trastuzumab and its biosimilars on cardiac function in HER2-positive early breast cancer patients: a single-center study","volume":"15","author":"Au","year":"2025","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.jaccao.2026.07.009_bib29","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/biomet\/80.3.557","article-title":"Checking the cox model with cumulative sums of martingale-based residuals","volume":"80","author":"Lin","year":"1993","journal-title":"Biometrika"},{"key":"10.1016\/j.jaccao.2026.07.009_bib30","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919887044","article-title":"Biosimilars for breast cancer: a review of HER2-targeted antibodies in the United States","volume":"11","author":"Miller","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.jaccao.2026.07.009_bib31","first-page":"1160","article-title":"Utilization and patient characteristics for the trastuzumab reference and biosimilars, and other human epidermal growth factor receptor 2 inhibitors in the United States","volume":"30","author":"Mai","year":"2024","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.jaccao.2026.07.009_bib32","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1200\/JCO.2015.64.5515","article-title":"Cardiac surveillance guidelines for trastuzumab-containing therapy in early-stage breast cancer: getting to the heart of the matter","volume":"34","author":"Dang","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaccao.2026.07.009_bib33","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10549-019-05453-z","article-title":"A pooled analysis of the cardiac events in the trastuzumab adjuvant trials","volume":"179","author":"de Azambuja","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jaccao.2026.07.009_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2019.07.015","article-title":"Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer","volume":"120","author":"Pivot","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaccao.2026.07.009_bib35","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10549-021-06192-w","article-title":"Incidence of cardiotoxicity and validation of the heart failure association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer","volume":"188","author":"Battisti","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jaccao.2026.07.009_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100772","article-title":"Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial","volume":"8","author":"de Azambuja","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.jaccao.2026.07.009_bib37","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1186\/1471-2407-14-625","article-title":"Effect and safety of dual anti-human epidermal growth factor receptor 2 therapy compared to monotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: a systematic review","volume":"14","author":"Zhang","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jaccao.2026.07.009_bib38","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.cjco.2021.06.019","article-title":"Pertuzumab cardiotoxicity in patients with HER2-Positive cancer: a systematic review and meta-analysis","volume":"3","author":"Alhussein","year":"2021","journal-title":"CJC Open"},{"key":"10.1016\/j.jaccao.2026.07.009_bib39","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1002\/ijc.28234","article-title":"Cardiac toxicity in breast cancer patients treated with dual HER2 blockade","volume":"133","author":"Valachis","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jaccao.2026.07.009_bib40","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1056\/NEJMoa2406070","article-title":"Survival with trastuzumab emtansine in residual HER2-Positive breast cancer","volume":"392","author":"Geyer","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaccao.2026.07.009_bib41","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejca.2019.11.023","article-title":"Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: pooled analysis in advanced HER2-positive breast cancer","volume":"126","author":"Pond\u00e9","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaccao.2026.07.009_bib42","doi-asserted-by":"crossref","first-page":"e811","DOI":"10.1161\/CIR.0000000000001056","article-title":"Cardio-oncology drug interactions: a scientific statement from the American Heart Association","volume":"145","author":"Beavers","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2026.07.009_bib43","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.cardfail.2024.08.045","article-title":"Cardio-Oncology and heart failure: a scientific statement from the heart failure Society of America","volume":"31","author":"Bloom","year":"2025","journal-title":"J Card Fail"},{"key":"10.1016\/j.jaccao.2026.07.009_bib44","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/jnci\/djs317","article-title":"Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study","volume":"104","author":"Bowles","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jaccao.2026.07.009_bib45","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.jcmg.2018.06.005","article-title":"Cardiotoxicity and cardiac monitoring among chemotherapy-treated breast cancer patients","volume":"11","author":"Henry","year":"2018","journal-title":"JACC Cardiovasc Imaging"}],"container-title":["JACC: CardioOncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087326002899?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087326002899?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:56:45Z","timestamp":1789073805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666087326002899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":43,"alternative-id":["S2666087326002899"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccao.2026.07.009","relation":{},"ISSN":["2666-0873"],"issn-type":[{"value":"2666-0873","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Cardiotoxicity of Biosimilar versus Reference Trastuzumab in Early HER2-Positive Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"JACC: CardioOncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccao.2026.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}